Atreca, Inc.: restructuring charge — Atreca suspends lead candidate ATRC-101, cuts 40% of staff; Q2 net loss $19.2M

Atreca, Inc.

Suspension of ATRC-101 development and ~40% workforce reduction; estimated restructuring costs of $1.6M in Q3 2023.
Q2 2023 net loss of $19.2M ($0.49 per share); cash and investments totaled $38.5M as of June 30, 2023.
R&D expenses $12.9M and G&A expenses $6.8M for Q2 2023, including stock-based compensation.
Focus shifts to preclinical ADC APN-497444; expects to nominate clinical candidate in 2023 and IND in late 2024/early 2025.
Cash runway expected to fund operations through early 2024; company evaluating additional cost-saving initiatives.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Atreca, Inc. announced a restructuring with charges of approximately $1.6 million affecting operations (approximately 40% of its current employees).

Type: restructuring
Charge: approximately $1.6 million
Affected area: operations
Headcount: approximately 40% of its current employees

Exact text from the filing

On August 10, 2023, the Company implemented and announced a corporate reorganization of its operations. As part of the reorganization, the Company is undertaking cost-saving initiatives, including a workforce reduction of approximately 40% of its current employees and the suspension of the development of ATRC-101, its former lead product candidate. The total cost related to the workforce reduction is estimated to be approximately $1.6 million, all of which is cash-based expenditures related primarily to severance payments.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001171843-23-005224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.